Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 4 days ago

Forte Biosciences, Inc.: MPM BioImpact LLC amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 13 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

MPM BioImpact LLC has amended its Schedule 13G beneficial ownership filing for Forte Biosciences, Inc., disclosing its stake in the clinical-stage biopharmaceutical company via SEC accession 0001687078-26-000026. The amendment updates the investment firm's reported position in Forte, though the filing summary did not specify the exact share count or percentage held. Schedule 13G filings are required of passive investors holding more than 5% of a company's voting securities, making the disclosure a signal of MPM BioImpact's continued institutional interest in the dermatology-focused developer. Investors will watch for further detail on the size and direction of the position, as well as any subsequent 13G or 13D amendments that could indicate a shift toward activist involvement. Forte's pipeline progress and capital position remain the key fundamental drivers alongside such ownership disclosures.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

MPM BioImpact LLC, Forte Biosciences, Inc.